Blood-based RNA biomarker for the early detection of ovarian cancer.

Tu-stroma, a serum extracellular vesicle long noncoding RNA, is elevated in STIC and early-stage HGSC and discriminates them from controls with AUCs up to 0.99.

• Why it matters: STIC, the precursor to high-grade serous carcinoma, is usually detected only after fallopian tube tissue is removed, leaving a gap for earlier, blood-based detection.
• What they did: Serum EV Tu-stroma was quantified by normalized EV Tu-stroma ΔC T in 506 individuals spanning histologically normal adnexa, benign-adnexal lesions, isolated STIC, and HGSC across FIGO stages I–IV, and compared with CA125 using paired ROC analyses.
• The result: Tu-stroma showed higher discrimination than CA125 for STIC versus controls (AUC 0.99 vs 0.59) and benign-adnexal masses (0.99 vs 0.31), and for HGSC versus controls (0.99 vs 0.96) and benign-adnexal masses (0.98 vs 0.84), with no systematic elevation in inflammatory/physiologic comparators (n=116) or nonovarian malignancies (n=160).

AI summary of the abstract · may contain errors · not medical advice · read the paper.